eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 69
Original paper

The prognostic significance of androgen receptor and β-catenin immunohistochemical expression in urothelial carcinoma with and without detrusor muscle invasion from an Egyptian institution

Shaimaa Elzamy, Abd Allah Ms, Wael Kandeel

Pol J Pathol 2018; 69 (3): 234-242
Online publish date: 2018/11/20
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Androgen receptor (AR) activation plays an important role in the promotion and progression of urothelial tumorigenesis. Also, dysregulation of the Wnt/β-catenin signaling pathway has also been linked to bladder cancer growth. However, cross talk between the two pathways in remains unclear in bladder cancer. This study investigated the prognostic significance of AR and β-catenin expression and their relationship to different clinic-pathological parameters, recurrence free and progression free survival.

106 urothelial carcinoma cases were used to study the immunohistochemical expression of AR and β-catenin. Log-Rank test to compare survival between groups.

Androgen receptor positivity was in 37 (34.9%) cases. Both aberrant β-catenin and AR positivity were associated with higher tumor grade (p = 0.033 and p = 0.037 respectively) and muscle invasion (p = 0.007 and p = 0.039 respectively). Aberrant β-catenin only showed statistically significant association with tumor diameter (p = 0.036), tumor stage (p = 0.038), LN metastasis (p = 0.001), tumor recurrence (p = 0.026) and tumor progression (p = 0.01). Cases with aberrant β-catenin showed higher AR positivity (p = 0.018).

Our study highlighted important information about the link between Wnt/β-catenin and AR pathway during the progression of transitional urothelial carcinoma with aberrant β-catenin could be used as a prognostic marker.

androgen receptors, β-catenin, non-detrusor muscle invasive urothelial carcinoma, detrusor muscle invasive urothelial carcinoma

Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010; 28: 409-428.
Miyamoto H, Miller JS, Fajardo DA, et al. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 2010; 60: 1-8.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
El-Sharkawi F, El Sabah M, Hassan Z, et al. The biochemical value of urinary metalloproteinases 3 and 9 in diagnosis and prognosis of bladder cancer in Egypt. J Biomed Sci 2014; 21: 72.
2004 hwneeCssrfN.
Hemelt M, Yamamoto H, Cheng KK, et al. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer 2009; 124: 412-419.
Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol 2017; 24: 730-734.
Hartge P, Harvey EB, Linehan WM, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990; 82: 1636-1640.
Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004; 10: 2208-2219.
Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 2008; 68: 9918-9927.
Schweizer L, Rizzo CA, Spires TE, et al. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol 2008; 9: 4.
Jung SJ, Oh S, Lee GT, et al. Clinical Significance of Wnt/beta-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer. World J Mens Health 2013; 31: 36-46.
Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-320.
Hu X, Ruan Y, Cheng F, et al. p130Cas, E-cadherin and beta-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol 2011; 18: 630-637.
Urakami S, Shiina H, Enokida H, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 2006; 12: 383-391.
Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.
Bakry OA, Samaka RM, Shoeib MA, et al. Immunolocalization of androgen receptor and estrogen receptors in skin tags. Ultrastruct Pathol 2014; 38: 344-357.
Boorman GA. Animal model of human disease: carcinoma of the ureter and urinary bladder. Am J Pathol 1977; 88: 251-254.
Okajima E, Hiramatsu T, Iriya K, et al. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res 1975; 3: 73-79.
McCahy PJ, Harris CA, Neal DE. The accuracy of recording of occupational history in patients with bladder cancer. Br J Urol 1997; 79: 91-93.
Birtle AJ, Freeman A, Munson P. The androgen receptor revisited in urothelial carcinoma. Histopathology 2004; 45: 98-99.
Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004; 64: 383-388.
Li Y, Izumi K, Miyamoto H. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol 2012; 42: 569-577.
Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004; 61: 332-353.
Chen F, Langenstroer P, Zhang G, et al Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. J Urol 2003; 170: 2009-2013.
Mashhadi R, Pourmand G, Kosari F, et al. Role of steroid hormone receptors in formation and progression of bladder carcinoma: a case-control study. Urol J 2014; 11: 1968-1973.
Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 2011; 29: 43-51.
Ruizeveld de Winter JA, Trapman J, Vermey M, et al. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 1991; 39: 927-936.
Boorjian SA, Heemers HV, Frank I, et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 2009; 16: 123-137.
Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011; 50: 931-944.
Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 2012; 109: 1716-1726.
Kashiwagi E, Fujita K, Yamaguchi S, et al. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. Cancer Biol Ther 2016; 17: 1188-1196.
Mir C, Shariat SF, van der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 2011; 108: 24-30.
Zhuang YH, Blauer M, Tammela T, et al. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 1997; 30: 556-562.
Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007; 99: 558-568.
Noronha RF, Rao BR. Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology 1986; 28: 401-403.
Botelho MC, Machado JC, Brindley PJ, et al. Targeting molecular signaling pathways of Schistosoma haemotobium infection in bladder cancer. Virulence 2011; 2: 267-279.
Vale N, Gouveia MJ, Rinaldi G, et al. The role of estradiol metabolism in urogenital schistosomiasis-induced bladder cancer. Tumour Biol 2017; 39: 1010428317692247.
Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harb Perspect Biol 2013; 5: a007898.
Gao C, Xiao G, Hu J. Regulation of Wnt/beta-catenin signaling by posttranslational modifications. Cell Biosci 2014; 4: 13.
Garcia del Muro X, Torregrosa A, Munoz J, et al. Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer 2000; 36: 357-362.
Syrigos KN, Harrington K, Waxman J, et al. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol 1998; 160: 1889-1893.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe